IFNA2 and COVID-19: We therefore used our antibody-binding assay to assess anti-IFNα2 and anti-IFNω IgG, IgA, and IgM autoantibodies in tracheobronchial secretions (TBSs) obtained from 88 of the severe COVID-19 patients in our cohort.